[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Institute on Aging (NIA)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":309},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,68,80,90,112,134,161,183,203,221,244,263,286],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053744",false,"NCT06274749","Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial","The Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults >= 55 Years Old. A Randomized Triple-Masked Controlled Clinical Trial","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availably for the duration of the study.\n* Male or female, age \\>= 55 years.\n* Able to speak and read English. (We do not have ready access to interpreters of different languages at the NIA Clinical Unit).\n* BMI \\>= 27.\n* Ability to take oral medication and be willing to adhere to the daily regimen.\n* Ability to perform walking and treadmill tests without physical limitations.\n* In good general health, as evidenced by medical history\u002Fphysical exam\u002Flaboratory results.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* History of diabetes requiring treatment with any glucose lowering drug(s).\n* Fasting glucose \\>= 126 on screening visit.\n* Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment.\n* Hospitalization within 12 months for myocardial infarction, coronary revascularization or bypass surgery or stroke.\n* History of autoimmune disease, e.g., Hashimoto s thyroiditis, Myasthenia Gravis or Rheumatoid Arthritis.\n* Uncontrolled thyroid disease.\n* Chronic liver disease indicated by medical history or one of the liver enzymes greater than 2 times the normal range.\n* History of chronic kidney disease or GFR \\\u003C60 mL\u002Fmin\u002F1.73 m\\^2.\n* Anemia (defined as hemoglobin level \\\u003C12 g\u002Fdl for men or \\\u003C 11 g\u002Fdl for women).\n* Poor venous access.\n* Uncontrolled hypertension as judged by the Investigator.\n* History of significant GI disease, e.g., IBS, Crohn s disease.\n* Active cancer or has had treatment for cancer in the last 1 year.\n* Medical condition requiring absolute and continuous need for long-term treatment with antibiotics, corticosteroids, immunosuppressors.\n* Currently pregnant or a nursing mother due to possible changes in hormones and metabolism.\n* History of, or laboratory evidence of HIV virus infection at Screening Visit.\n* History of, or laboratory evidence of Hepatitis B or C at Screening Visit.\n* Positive urine drug screen at Screening Visit (unless taking prescribed medication and at the discretion of the PI).\n* Reports claustrophobia and\u002For is not eligible to have an MRI as per the MRI eligibility form.\n* Weight \\>= 300 lbs (MRI scanner weight limit).\n* Hip or knee replacement or other medical condition that prevents MRI research scans from being performed.\n* Diagnosed with cognitive impairment that clearly prevents the participant from providing informed consent.\n* Current smoker or tobacco use in the past year.\n* History of substance abuse, including marijuana use in the past year.\n* On average, consumes more than 1 alcoholic drink per day.\n* Any other condition which in the investigator s opinion may adversely affect the subject s ability to complete the study or its measures or which may pose significant risk to the subject.","ALL","55 Years","100 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"NA","Background:\n\nAs people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose.\n\nObjective:\n\nTo learn if UA improves levels of insulin and other hormones that help control blood glucose.\n\nEligibility:\n\nPeople aged 55 years and older with a body mass index of 27 or higher.\n\nDesign:\n\nParticipants will have 6 clinic visits over 8 weeks.\n\nParticipants will be screened. They will have a physical exam with blood and urine tests and a test of their heart function.\n\nUA gelcaps are taken by mouth every morning at home. Half of participants will take UA. The other half will take a placebo. The placebo looks like the study drug but does not contain any medicine. Participants will not know which they are taking.\n\nParticipants will have tests during the study including:\n\nOral glucose tolerance: Participants will drink a sweet liquid. Blood will be drawn at intervals over the next 3 hours.\n\nContinuous glucose monitor: A sensor with a needle that goes just under the skin will be placed on the upper arm. Participants will wear this sensor throughout the study.\n\nExercise. Participants will walk on a treadmill while their heart rate, hearth rhythm, and blood pressure are monitored. They will walk in a hallway at normal and fast paces.\n\nImaging scans of the thigh; scans of the brain are optional....",[26],"Healthy Volunteer",[28,29,30,31,32],"Urolithin A","GLUCOSE METABOLISM","Insulin","Muscle Strength","Microbiomes","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":20},"2026-07-16",{"date":41,"type":20},"2027-03-31",{"name":43,"class":44},"National Institute on Aging (NIA)","NIH",1,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100053680","NCT07099053","Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging","Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)","* INCLUSION\u002FEXCLUSION CRITERIA:\n* Participants are men and women 55 years and older drawn from the BLSA sample and thus, represent the gender\u002Fethnic characteristics of this study group. Enrollment is defined as the initial imaging session of the planned longitudinal study.\n* Inclusion criteria: BLSA participants who do not meet exclusion criteria and have had or agreed to have an MRI under the BLSA study.\n* Participants who lack capacity to consent will not be enrolled in the study. If the participant loses capacity to consent over the course of follow-up they will be removed them from the study. Competency to consent is assessed as part of the BLSA visit and we will not include people who are not competent to provide consent.\n\nEXCLUSION CRITERIA:\n\n* Preexisting central nervous system diseases\n* Weight over 300 lbs.\n* Active metastatic cancer (except basal cell cancer)\n* Implanted electronic hearing devices\n* Breast Cancer with radiation treatment\n* Lymphoma\n* Pacemaker\n* Brain tumor\n* Shrapnel\n* Schizophrenia\n* Bipolar disorder\n* Epilepsy\n* Language barrier that makes it difficult to understand participant.\n* Aneurisms greater than 3mm\n* Aneurysm clips\n* Parkinson s disease\u002FPD medications\n* Huntington s disease\n* Severe Endocrinopathy- treated thyroid conditions ok; treated, controlled diabetes ok. (exclude HbA1c over 8 which is poorly controlled diabetes)\n* Diagnosis of dementia or mild cognitive impairment\n* Younger than 55 years of age\n* Pregnancy\n* Ineligible for MRI\n* History of stroke or documented TIAs requiring hospitalization\n* Known brain vascular malformations or adenomas\n* History of significant radiation exposure\n* Those with a Blessed score of 4 or more with the BLSA will be reviewed at a research diagnostic case conference to rule out dementia diagnoses prior to enrollment.",true,"110 Years",{"count":55,"type":20},400,"OBSERVATIONAL","Background:\n\nSome people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or other medical issues.\n\nObjective:\n\nTo learn how amyloids may affect brain structure and function as people age.\n\nEligibility:\n\nPeople aged 55 years and older who are enrolled in the Baltimore Longitudinal Study of Aging.\n\nDesign:\n\nParticipants will have imaging scans and other tests every 1 to 4 years, depending on their age. Those 80 and older will be scanned yearly. These scans will be done during regular BLSA visits.\n\nThe scans will be positron emission tomography and computed tomography (PET CT). Participants will be given fluid through a tube inserted into a vein in their arm. The fluid is a tracer that will cause the amyloids to light up in the images. Then they will lie on a bed with their head inside a PET CT scanner. They will lie still for about 30 minutes.\n\nParticipants will have tests to assess their memory and other mental skills. They will answer questions about their mood and daily life. These tests will take about 40 minutes to complete; they may be done in person or by phone.\n\nParticipants will give a contact number for someone who can answer questions about the participant s daily routine. These questions may be answered in person or by phone.\n\nParticipants will be in this study for 5 years.",[59],"Aging",[61,62],"Amyloid","PET",{"date":36,"type":37},{"date":39,"type":20},{"date":66,"type":20},"2029-12-12",{"name":43,"class":44},{"id":69,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":70,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":71,"keywords":72,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":79,"locationsCount":45},"100600558",{"count":55,"type":20},[59],[61,62],"2026-07-01",{"date":75,"type":37},"2026-07-02",{"date":77,"type":20},"2026-07-07",{"date":66,"type":20},{"name":43,"class":44},{"id":81,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":24,"conditions":84,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":89,"locationsCount":45},"100537201",{"count":19,"type":20},[23],[26],[28,29,30,31,32],{"date":75,"type":37},{"date":77,"type":20},{"date":41,"type":20},{"name":43,"class":44},{"id":91,"slug":4,"hasResults":10,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":52,"sex":15,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":45},"100313876","NCT03366168","Taste Bud-Derived Stem Cells in Humans","A Pilot Study of Taste Bud-Derived Stem Cells in Humans","* INCLUSION CRITERIA:\n* Age 18 years and older\n* Healthy (see exclusion criteria below)\n* Are able to understand the study risks and procedures, and consent to participate in the study.\n* Are able to read and speak English.\n\nEXCLUSION CRITERIA:\n\n* Have less than 40 fungiform papillae on the anterior third portion of the tongue as evidenced by tongue photo taken during the screen visit.\n* Does not agree to the use of their tissue samples to produce stem cells.\n* A medical condition that requires the use of chronic anticoagulant medication use such as warfarin, clopidogrel, heparin or antiplatelet agents other than low dose aspirin (81mg).\n* History of increased bleeding due to either a known medical condition or an undiagnosed cause.\n* Active infections or chronic conditions that would prevent access to the biopsy area.\n* Taking non-steroidal anti-inflammatory agents (NSAIDs) such as Motrin (Ibuprofen), Advil (Ibuprofen) or Naprosyn (Naproxen) and the participant is unable to stop taking them 4 days before and 3 days after the final biopsy procedure.\n* Taking more than 81 mg of aspirin a day and the participant is unable to stop taking it for 4 days before and 3 days after the biopsy procedure.\n* Allergic to Lidocaine (Xylocaine) or any other local anesthetic or the participant has had in the past a severe allergic reaction to similar drugs.\n* Have taken steroids, other than ocular within 30 days of their scheduled biopsy procedure.\n* HIV virus infection.\n* Hepatitis B or C.\n* Kidney disease (Creatinine greater than1.5 mg\u002Fdl or calculated creatinine clearance less than 50 cc\u002Fmin).\n* Liver disease (ALT, AST or alkaline phosphatase twice the normal serum concentration).\n* Severe gastrointestinal diseases such as Crohn s disease or ulcerative colitis requiring continuous treatment.\n* History of severe pulmonary disease such as chronic obstructive pulmonary disease (COPD) or asthma requiring continuous medication use.\n* History of using any tobacco products within the past six months.\n* History of severe psychiatric conditions associated with behavioral problems or requiring chronic medical treatment.\n* Currently pregnant or breastfeeding.\n* Current illness that as judged by the study physician substantially increases the risks associated with the tongue biopsy (active infections, allergies, etc.).","18 Years","120 Years",{"count":99,"type":20},250,"Background:\n\nStem cells are found in body tissues. They can regenerate into more of the same cells or become other types of cell. Researchers want to use stem cells from taste buds to try to make cells that secrete insulin. Taste buds are found mostly on the tip and sides of the tongue. Researchers also want to study if the number of taste buds and stem cells decrease as people age. They will remove small pieces of tongue tissue (about the size of a pen tip). The taste buds will grow back. It is hoped that studying taste bud stem cells can lead to new diabetes treatments.\n\nObjectives:\n\nTo see if stem cells from taste buds can be isolated in humans.\n\nEligibility:\n\nHealthy adults at least 18 years old\n\nDesign:\n\nParticipants will be screened with:\n\n* Medical history\n* Physical exam\n* Blood and urine tests\n* Tongue photograph and mouth inspection. Food coloring will be applied to the tongue.\n\nParticipants will have 1 study visit. They will not eat or drink anything 8 hours before.\n\n* They will give blood and urine samples.\n* They will have a tongue biopsy. Vital signs will be checked. The inside of the mouth will be examined. The tongue may be cleaned. The tongue will be numbed. Five small pieces of tissue will be taken with a small scissor. Any bleeding will be blotted with cotton and should stop in minutes.\n* Participants will be monitored for about 30 minutes. They will get a snack or meal.\n* They will be told how to take care of the tongue for the rest of the day.\n\nParticipants will be called a week later to see how the\n\n...",[102],"Diabetes",[102,104,30,105],"Fungiform Papillae","Natural History",{"date":75,"type":37},{"date":108,"type":37},"2017-12-18",{"date":110,"type":20},"2026-12-31",{"name":43,"class":44},{"id":113,"slug":4,"hasResults":10,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":52,"sex":15,"minAge":96,"maxAge":97,"enrollmentInfo":117,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":4,"leadSponsor":133,"locationsCount":45},"100065540","NCT00104325","Cytapheresis of Volunteer Donors","* INCLUSION CRITERIA:\n* Normal healthy males and females, age 18 years and older\n* Adequate venous access in bilateral upper extremities to accommodate at least a #18 gauge dialysis needle.\n* Willingness and ability to come to the NIA Apheresis Unit at Harbor Hospital in Baltimore for a blood collection procedure approximately every 56 days.\n\nEXCLUSION CRITERIA:\n\n* Unable to verify identification of volunteer by state issued ID card, driver s license, or military ID. Participants earning greater than $600.00\u002Fyear are issued a 1099 form, therefore, positive identification is required.\n* Unable to provide informed consent\n* Weight less than 110 pounds as mandated by AABB guidelines.\n* Chronic Immunosuppressive medications such as Steroids, Cellcept or Sirolimus. Steroids given for minor illness ok if taken more than 6 weeks before any cytapheresis procedure. Immunosuppressive medications may not be used at the time of the cytapheresis procedure as they decrease circulating white blood cells.\n* Test results are positive for viral infections such as HIV, Hepatitis B or C and RPR. Researchers are seeking healthy, pristine cells. Due to the ongoing nature of these chronic viral and bacterial infections, the white cell populations in the peripheral blood will change. Researchers want to study changing white cell populations as a factor of aging only and not those altered by infections.\n* Ongoing risk factors for HIV or Hepatitis B or C such as: intravenous drug use, non-monogamous unprotected intercourse, or chronic use of clotting factor concentrates such as prothrombin complexes, Factor XIII or Factor VIIa. These viruses weaken the immune system and cause changes in the white blood cells.\n* Risk factors for Creutzfeldt-Jakob disease such as: a relative with the disease, received beef insulin or growth hormone from human pituitary glands, or residency\u002Ftravel to high risk countries (complete list of countries located in the Cytapheresis Screening manual kept in the NIA apheresis unit). This is a transmittable infectious disease with a very long incubation period.\n* Major medical illnesses such as any type of liquid or solid tumor cancer, diabetes, history of deep vein thrombosis, organ or bone marrow transplant, or liver, kidney, heart or lung disease.\n* A medical finding that shows a participant could not safely go through this procedure. (such as Parkinson s disease, dementia or any uncontrolled behavior that would place the participant s safety at risk)\n* Major infectious diseases such as Chagas disease, babesiosis, syphilis or malaria\n* Bleeding conditions such as hemophilia or von Willebrand s disease.\n* Significant abnormalities are found in the results of blood tests such as elevated liver enzymes, abnormal kidney function, positive viral titers, fasting blood glucose greater than 120.\n* On any medication that can alter white blood cell function such as chronic steroid use, histamine-2 blockers, antivirals or chemotherapy. (complete list located in the Cytapheresis Screening manual stored in the NIA Apheresis unit).\n\nIn addition, eligible participants may not be able to participate in a specific cytapheresis procedure but might be eligible at a later date for:\n\n1. Pregnancy and Nursing Mothers - Females who are pregnant or who have had a pregnancy in the last 6 weeks are temporarily deferred. They may resume apheresis participation 6 weeks after delivery or cessation of lactation and have been cleared by their obstetrician or primary care physician.\n2. Medications: Volunteers taking the following medications would be deferred:\n\n   * Antibiotics, antifungals, antimalarials: Deferred for 2 weeks after course has been completed and volunteer is feeling well.\n   * Temporary steroids (tapers): Deferred for 72 hours after symptoms are resolved and prescription is completed if taken orally, intravenously, or intramuscular. No deferral if taken intranasal or for joint injection.\n   * Hepatitis B immune globulin: Volunteers are deferred 6 months if given after exposure to hepatitis B to insure the volunteer has not been infected. If administered for prophylaxis, no deferral is necessary.\n   * Live Attenuated Virus Vaccinations: Defer for 4 weeks if symptom-free.\n   * Inactivated (Killed Virus) Vaccinations: Defer for 2 weeks if symptom-free.\n   * Rabies Vaccine: Deferred for 1 year if given for rabies exposure; otherwise accept immediately if symptom-free.\n   * Smallpox Vaccine: Deferred until the scab has separated from the skin spontaneously or 21 days from date of immunization, whichever is longer, if volunteer had no other symptoms or complications. Visual verification of absence of vaccine scab is required. If scab was otherwise removed (not spontaneously separated), defer for 2 months after vaccination date.\n   * Blood thinners such as Plavix, Ticlid or Lovenox. Deferral for 5 days after last dose to decrease bleeding risk at needle puncture sites. Participants are not deferred for the use of aspirin or aspirin products.\n   * Experimental Medication or Unlicensed (Experimental) Vaccine is usually associated with a research protocol and the effect on blood donation is unknown. Deferral is one year unless otherwise indicated by the Principal Investigator.\n3. Temporary health issues\n\n   * Infection or fever: Deferred until 2 weeks after antibiotics are completed and volunteer is feeling well.\n   * Surgical Procedures: Deferred for 3 months after procedure and released to return to normal activities by primary care physician or surgeon.\n   * Close contact with someone else s blood, accidental needle-stick, treatment for syphilis or gonorrhea Volunteers are deferred for 6 months to insure they have not been infected. Viral\u002Fserology testing will be repeated and verified as negative prior to apheresis procedure.\n   * Factors that are high risk (but are non on-going) for HIV, Hepatitis B or C such as: (Volunteers will be deferred for 6 months after to insure they have not been infected with an infectious disease or virus. Viral testing and annual labs will be repeated and verified as within normal limits prior to apheresis procedure)\n\n     i. Having sexual contact with anyone who has HIV\u002FAIDS or has had a positive test for the HIV\u002FAIDS virus\n\n   ii. Received money, drugs or other payment for sex or having sexual contact with a prostitute or anyone else who takes money or drugs or other payment for sex\n\n   iii. Had sexual contact with anyone who has hemophilia or has used clotting factor concentrates.\n\n   iv. Has used needles to take drugs, steroids or anything NOT prescribed by their doctor or had sexual contact with anyone who has ever used needles to take drugs or steroids, or anything NOT prescribed by their doctor.\n\n   v. Had sexual contact with or living with anyone who has hepatitis.\n\n   vi. Had a tattoo using non-sterile needles or reused ink.\n\n   vii. Had a body piercing that used non-sterile needles or multi-use equipment.\n\n   viii. Has been in juvenile detention or prison for more than 72 hours.\n   * Had close contact with someone who had a smallpox vaccination such as touching the vaccination site, handling bedding or clothing that has been in contact with an unbandaged vaccination site to insure they have not been infected: Deferral is 2 months if volunteer is symptom-free.\n   * Anemia\u002FLeukopenia\u002FThrombocytopenia:\n\n     i. Female volunteers with a hemoglobin of \\\u003C 11.0 or hematocrit \\\u003C35, or males with a hemoglobin of \\\u003C12.5 or hematocrit \\\u003C38 may return in 8 weeks to repeat labs to verify anemia. Deferred until values return to the levels stated required levels.\n\n   ii. White blood cell count \\\u003C3.0 in African-American participants or \\\u003C3.5 in all other races. Deferred until values return to the levels stated required levels.\n\n   iii. Platelet count \\\u003C150,000. Deferred until values return to the levels stated required levels.\n\n   iv. Mean Corpuscular Volume (MCV) \\\u003C80. Deferred until values return to the levels stated required levels.\n\n   v. Whole blood donation (450 mL): Deferred for 56 days from date of last donation as mandated by AABB guidelines.\n\n   vi. Double unit red cell donation: Deferred for 112 days (16 weeks) as mandated by AABB guidelines.\n\n   vii. Platelet or plasma donation: Deferred for 28 days from date of last donation as mandated by AABB guidelines.\n\n   viii. Leukocyte donation: Deferred for 56 days from date of last donation as mandated by AABB guidelines.\n   * Received blood transfusion, transplant such as tissue, or had a graft such as bone or skin: Deferral is for 12 months to insure volunteer has not acquired an infectious disease. Annual laboratory testing will be repeated prior to apheresis procedure.\n   * It is less than six weeks since participation in another research study which is felt by the Principal Investigator to be incompatible with this study. (for example: studies that collect blood, investigational drug studies, vaccine trials, etc)\n4. Travel:\n\n   * Malaria-endemic countries: Volunteers who are residents of such countries will be deferred for 3 years after departure from the country if they remain free from unexplained symptoms suggestive for malaria. Residence is defined as a continuous stay of longer than 5 years in a country or countries having any malaria-endemic area. Donors who are not prior residents of malaria-endemic countries and travel to a malaria-endemic area will be deferred for 12 months after departure from that area. The duration of travel to a malaria-endemic area is defined as more than 24 hours to less than 5 years. Note that a passage greater than 24 hours through a malaria-endemic area while on route to a malaria-free area is considered a sufficient possible exposure to trigger deferral.\n\n(A complete list of malarial-endemic countries is kept in the Cytapheresis Screening Manual and is stored in the NIA Apheresis Unit.)",{"count":118,"type":20},10000,"Background:\n\n\\- National Institute on Aging researchers are looking at studies that require large numbers of white blood cells for lab use. Standard blood samples do not provide enough white blood cells for these studies. Researchers want to use cytapheresis to collect white blood cells from volunteer donors. This procedure can collect larger amounts of white blood cells and reduce the amount of fluid and other cells that are lost.\n\nObjectives:\n\n\\- To use cytapheresis to collect white blood cells for study.\n\nEligibility:\n\n\\- Healthy blood donors at least 18 years of age.\n\nDesign:\n\n* Participants will be screened according to the usual blood donation procedures.\n* Participants will provide white blood cells through cytapheresis. The blood cells will be collected in a machine that separates the white blood cells from the rest of the blood. The rest of the blood will be returned to the donor.\n* Participants may have this type of donation every 56 days (six times per year). They will be asked to become a repeat donor. A donation schedule may be set up.\n* Once a year, participants will have blood tests to continue to be eligible as a donor.",[121],"Healthy Volunteers",[123,124,125,126,127,105],"Cell Separation","White Blood Cells","Immune Studies","Cell Function","Machine Collection","2026-06-27",{"date":130,"type":37},"2026-06-30",{"date":132,"type":37},"2003-01-30",{"name":43,"class":44},{"id":135,"slug":4,"hasResults":10,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":52,"sex":15,"minAge":140,"maxAge":97,"enrollmentInfo":141,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":45},"100235143","NCT02339012","Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)","The Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)","* Since the study of gene expression and epigenetic regulation are essential aims of GESTALT, all participants are required to consent to DNA\u002FRNA testing and storage at all visits. Participants that refuse genetic testing and storage will not be eligible to participate or to continue to participate in the study.\n\nThe criteria below for each group pertains only to the Screening and Baseline Visits, except where otherwise noted. If any of the conditions develop while the participant is in the study, the participant remains in the study. However, participants that develop severe cognitive problems and are diagnosed by the cognition group with dementia, will no longer be able to participate in the study.\n\nINCLUSION CRITERIA for the Healthy Group:\n\n* Age greater than or equal to 20 years of age.\n* Are willing to return every 2 years for study visit procedures.\n* Agree to genetic (DNA\u002FRNA) sample collection, analysis and storage.\n* Have good venous access for cytapheresis and are in good health as determined by the Apheresis Health History Questionnaire and are found eligible for apheresis (Apheresis Eligibility form).\n* Weigh greater than or equal to 110lbs and a body mass index (BMI) \\\u003C 30.\n* Do not have established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder).\n* Do not have autoimmune diseases such as Hashimoto's thyroiditis, Myasthenia Gravis or Rheumatoid arthritis.\n* Report that they are able to perform daily self- care without assistance.\n* Report that they able to walk independently for at least 400 meters without assistance and without developing severe symptoms.\n* Report they are able to perform normal activities of daily living without shortness of breath (walking or climbing stairs) or other severe symptoms.\n* Do not have cognitive impairment based on mental status screening tests and evaluations and in the absence of any drug treatment.\n* Do not have a history of cardiovascular disease or cerebrovascular disease including angina (requiring treatment), myocardial infarction, congestive heart failure, uncontrolled hypertension, pacemaker, stroke, or transient ischemic attacks (TIA).\n* Do not have a history of diabetes (requiring any medical treatment other than diet and exercise) and their fasting Glucose is \\\u003C126 mg\u002FdL.\n* Do not have active (any activity in the last 10 years) cancer, except for locally limited squamous and basal cell cancer.\n* Do not have clinically significant hormonal dysfunction (Self-reported or laboratory values out of range. Mild hypothyroidism in participants over 60 is not considered exclusion).\n* Do not have a history of neurological diseases or birth defects (other than minor anatomical abnormalities, which do not affect physical and\u002For cognitive function).\n* Do not have a history of kidney or liver disease (associated with reduced kidney or liver function).\n* Do not have a history of severe gastrointestinal (G.I.) diseases, with symptoms or requiring chronic treatment such as gastroesophageal reflux disease (GERD), Crohn s disease or ulcerative colitis.\n* Do not have a history of severe pulmonary disease such as chronic obstructive pulmonary disease (COPD) or asthma requiring continuous medication use.\n* Do not have muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and\u002For chronic pain).\n* Do not have a history of severe psychiatric conditions associated with behavioral problems or requiring absolute and continuous need for medical treatment.\n* Do not have any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, H2 blockers and\u002For proton pump inhibitors, or pain medications.\n* Do not have a medical condition that requires the use of chronic anticoagulant medication such as Coumadin, heparin, or antiplatelet agents other than low dose aspirin.\n* Do not have important sensory deficits (legally blind and\u002For any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent).\n* Are able to read and speak English.\n* Are able to understand the study risks and procedures, and consent to participate in the study.\n* Not currently pregnant or a nursing mother.\n* Do not currently smoke and have not smoked in the past 3 months.\n* Veins are adequate for cytapheresis.\n* No current illness that as judged by the study physician substantially increases the risks associated with cytapheresis (active infections, allergies, etc.).\n* No history of allergy to acid- citrate- dextrose (ACD) anticoagulant.\n* No history of an active bleeding disorder such as hemophilia or Von Willebrand disease.\n* No history of seizures within the last 3 months.\n* No history of Lyme disease, unless six weeks' post treatment and no new symptoms, of Chagas disease, Babesiosis, or Leishmanias.\n* Are not claustrophobic and are eligible to perform 3TMRI as per the MRI eligibility form.\n* Do not have hip or knee replacements or other medical conditions that prevent 3TMRI research scans from being performed.\n\nINCLUSION CRITERIA for the Non-Healthy-or-Frail and Frail groups:\n\n* Age \\>= 20 years of age in the NHF group.\n* Age \\>= 50 years of age in the F group.\n* Are willing to return every 2 years for study visit procedures.\n* Agree to genetic (DNA\u002FRNA) sample collection, analysis, and storage.\n* Have good venous access for blood sampling.\n* Weigh \\>= 110lbs and a body mass index (BMI) \\\u003C= 35.\n* Do not have established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder).\n* Do not have important sensory deficits (legally blind and\u002For any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent).\n* Are able to read and speak English.\n* Are able to understand the study risks and procedures, and consent to participate in the study.\n* Not currently pregnant or a nursing mother.\n* No current acute medical condition.\n* No history of an active bleeding disorder such as hemophilia or Von Willebrand disease.\n* No history of seizures within the last 3 months.\n* Are not claustrophobic and are eligible to perform 3TMRI as per the MRI eligibility form.\n* Do not have other medical conditions that prevent 3TMRI research scans from being performed.\n* Frail participants meet the A and B criteria as reported.\n* Not-Healthy-or-Frail participants will not be eligible for the Healthy group because of medical or functional problems and also do not meet the criteria for the Frail Group.\n\nParticipant Exclusion Criteria:\n\nThese criteria pertain to the Screening and Baseline Visits. If conditions considered as exclusion criteria for study entry develop any time after the Baseline evaluation, the participant remains in the study.\n\nExclusion Criteria:\n\n* HIV virus infection (all groups).\n* Hepatitis B or C (all groups).\n* Active syphilis, gonorrhea or TB requiring treatment (all groups).\n* WBC \\\u003C3,000 or \\> 12,000\u002Fk\u002FmicroL (only Healthy group).\n* Platelets \\\u003C 100,000 or \\>600,000 k\u002F microL (only Healthy group).\n* Hemoglobin \\\u003C 11.0 gm\u002FdL in women and \\\u003C 12.0 gm\u002FdL in men (only Healthy group).\n* GFR \\\u003C50 mL\u002Fmin\u002F1.73 m\\^2 (only Healthy group)\n* GFR \\\u003C= to 30 (only non-Healthy-or-Frail group or Frail group)\n* Bilirubin \\> 1.5 mg\u002Fdl (unless higher levels can be ascribed to Gilbert's disease (only Healthy group).\n* ALT, AST, or alkaline phosphatase twice the normal serum concentration (only Healthy group).\n* Corrected calcium \\\u003C 8.5 or \\> 10.7 mg\u002Fdl (all groups).\n* Albumin \\\u003C 3.1 g\u002Fdl (only Healthy group).\n* Cholesterol, LDL and\u002For Triglycerides \\>1.5x normal (only Healthy group).\n* Positive Urine Drug Screen (unless taking prescribed medication and at the discretion of the PI) (all groups).\n* Currently pregnant or a nursing mother (all groups).\n\nFurthermore, if the participant is found eligible at Screening and Baseline but fails a urine drug screen (unless taking a prescribed medication and at the discretion of the PI) at any of the subsequent visits, the participant will be asked to return to repeat the test and if positive, will no longer be eligible to participate in the study.","20 Years",{"count":142,"type":20},900,"Background:\n\n\\- Biomarkers are substances in people s blood and tissues. They help researchers understand diseases and signs of aging. Scientists want to do more research on biomarkers to find ways to improve quality of life in old age.\n\nObjective:\n\n\\- To learn more about biomarkers and their relationship to aging.\n\nEligibility:\n\n\\- Adults at least 20 years old who weigh at least 110 pounds and have a body mass index below 30. They must agree that their genetic samples can be collected, studied, and stored.\n\nDesign:\n\n* Participants will be screened with medical history, physical exam, EKG and blood and urine tests.\n* Participants will have 3-day visits. They will return every 2 years.\n* All visits include:\n* Blood and urine collection\n* Physical performance tests\n* Health questionnaires\n* Memory and problem-solving tests\n* Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT) scans.\n* Muscle metabolism\u002F exercise tests\n* Taste strips\n* Muscle and\u002For skin biopsies\u002F red light therapy\n* Retinal imaging\u002F eye tracking\n* Sleep study\n* ODD visits also include:\n* Cytapheresis\n* Bone marrow aspirate\n* EVEN visits also include:\n* Hyperglycemic CLAMP\n* Lumbar Puncture (LP)\n* Continuous Glucose Monitor (CGM)",[121,145,146],"Non-Healthy\u002FNon-Frail","Frail",[148,149,150,151,152,105],"Genome Wide Association","Biomarkers","Methylation","Phenotype","Cytometry","2026-06-23",{"date":155,"type":37},"2026-06-24",{"date":157,"type":37},"2015-03-15",{"date":159,"type":20},"2099-12-31",{"name":43,"class":44},{"id":162,"slug":4,"hasResults":10,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":52,"sex":15,"minAge":96,"maxAge":97,"enrollmentInfo":166,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":45},"100210276","NCT02014246","Genetic Characterization of Movement Disorders and Dementias","* INCLUSION CRITERIA\n\nFor Patients:\n\n* Diagnosis of a movement disorder or dementia by a neurologist or other qualified professional and accompanied by sufficient clinical and\u002For laboratory evidence to support the diagnosis\n* Confirmation of a movement disorder or dementia by study investigators or a qualified clinician by physical examination and\u002For review of medical records\n* Ages 18 and above\n* Able to provide consent or, in the case of minors, or cognitive impairment, have a legally-authorized representative to provide consent\n* Able to understand and participate in study procedures or for those without consent capacity, able to participate in study procedures AND has a legally authorized representative that understands the study procedures and can consent on their behalf.\n\nFor unaffected family members of patients:\n\n* Unaffected relative of a patient diagnosed with a movement disorder or dementia enrolled in this protocol. For these purposes, we define a family member as an individual for which there is a demonstrable relationship with the proband in the pedigree. This is a standard approach used in family-based studies. Furthermore, the related patient (defined as a family member diagnosed with the disease of interest) must be enrolled in the study.\n* Ages 18 and above\n* Able to provide consent\n* Able to understand and participate in study procedures\n\nFor unrelated healthy control individuals:\n\n* Be in good general health\n* Have no known movement disorder or dementia, or family member with a movement disorder or dementia\n* Age 18 and above\n* Able to provide consent\n* Able to understand and participate in study procedures\n\nEXCLUSION CRITERIA\n\nFor patients:\n\n-An identifiable, non-genetic etiology for the movement disorder or dementia, such as a specific environmental exposure, birth injury, metabolic disorder, or brain infection such as encephalitis\n\nFor all participants:\n\n* Clinically significant anemia that would make phlebotomy unsafe, and participant unwilling to provide saliva sample.\n* Clinically significant bleeding that would make phlebotomy unsafe, and participant unwilling to provide saliva sample.\n* Any medical condition that would make phlebotomy unsafe or undesirable, such as a serious medical illness like unstable heart disease, or unstable chronic obstructive pulmonary disease, and participant unwilling to provide saliva sample.",{"count":167,"type":20},12000,"Background:\n\nThere are two basic types of movement disorders. Some cause excessive movement, some cause slowness or lack of movement. Some of these are caused by mutations in genes. On the other hand, dementia is a condition of declining mental abilities, especially memory. Dementia can occur at any age but becomes more frequent with age. Researchers want to study the genes of families with a history of movement disorders or dementia. They hope to find a genetic cause of these disorders. This can help them better understand and treat the diseases. This study will not be limited to a particular disorder, but will study all movement disorders or dementias in general. This study will perform genetic testing to identify the genetic causes of movement disorders and dementia. Today, genetic testing can be done to analyze multiple genes at the same time. This increases the chances of finding the genetic cause of movement disorders and dementias.\n\nObjectives:\n\nTo learn more about movement disorders and dementia, their causes, and treatments.\n\nEligibility:\n\nAdults and children with a movement disorder or dementia, and their family members.\n\nHealthy volunteers.\n\nDesign:\n\nParticipants will be screened with medical history and blood tests. Some will have physical exam.\n\nParticipants will give a blood sample by a needle in the arm. This can be done at the clinic, by their own doctor, or at home. Alternatively, a saliva sample may be provided if a blood sample cannot be obtained.\n\nParticipants can opt to send an extra blood sample to a repository for future study. Genetic test will be done on these samples. The samples will be coded. The key to the code will remain at NIA. Only NIA investigators will have access to the code key. Participants can request to receive results of the tests.\n\nParticipation is generally a single visit. Participants may be called back for extra\n\n...",[170,171],"Dementia","Movement Disorder",[173,174,175,176,105],"Movement Disorders","Polymorphisms","DNA","Lymphoblastoid Cell Lines",{"date":155,"type":37},{"date":179,"type":37},"2003-07-14",{"date":181,"type":4},"2059-12-31",{"name":43,"class":44},{"id":184,"slug":4,"hasResults":10,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":52,"sex":15,"minAge":96,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100071427","NCT00182858","Tissue Procurement for Biomedical Research","* INCLUSION CRITERIA:\n* Age 18 or older.\n* Identified by the investigator , researcher, or physician to have a condition of interest for exploratory studies related to the participant s illness or other feature that offers the possibility of generation of hypotheses for future study.\n* Healthy volunteers, willing to provide their samples.\n\nEXCLUSION CRITERIA:\n\n* The participant would be subjected to diagnostic and\u002For therapeutic procedures that are not necessary for clinical management.\n* Excessive blood loss if this phlebotomy plus other research participation and\u002For clinical evaluation will result in blood loss of greater than 1 unit (400 ml, 1 pint) over an 8-week period.\n* Inability to give informed consent.","99 Years",{"count":190,"type":20},5000,"The need to obtain human tissue for methods development and disease correlation is frequent in Biomedical Research Center laboratories. This protocol is designed to create the opportunity to obtain such tissue samples including: blood, urine, saliva, sweat, feces, hair and nail clippings, nasal scraping, muscle, fat, skin and taste buds. It may also include samples taken during a surgical procedure, including: fluid from around the spinal column, heart, lungs and abdomen; fat, muscle, connective tissue and organs (liver, bladder, heart, kidney and skin).\n\nInformation derived from such studies is for research purposes only and is not provided to the participants or their health care provider. Samples will be coded (no names) and identifying information linking the participant to the sample will be maintained in a secure location by the P.I. and Study Coordinator.\n\nParticipants will be 18 years or older and have been identified by the investigator and\u002For physician to have a condition of interest for exploratory studies related to the participant s illness or other feature that offers the possibility of creating information that leads to scientifically useful and important studies. Participants could also be healthy volunteers, willing to provide their samples. These samples could be requested by an investigator to be used as age, gender, race and\u002For ethnicity-matched controls or to calibrate or compare and contrast across lab equipment. Participants will be excluded if obtaining the sample would be over and above usual clinical care, would result in excessive blood loss, or the individual is unable to provide informed consent.\n\nThe expected outcome is to provide investigators with the opportunity to obtain tissues of interest for laboratory evaluation....",[193],"Normal Volunteers",[195,196,105],"Biologic Sample Collection","Tissue Procurement",{"date":155,"type":37},{"date":199,"type":37},"2003-06-26",{"date":201,"type":4},"2028-12-31",{"name":43,"class":44},{"id":204,"slug":4,"hasResults":10,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":52,"sex":15,"minAge":140,"maxAge":97,"enrollmentInfo":209,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":4,"leadSponsor":220,"locationsCount":45},"100075199","NCT00233272","Baltimore Longitudinal Study of Aging","The Baltimore Longitudinal Study of Aging (BLSA)","* INCLUSION CRITERIA:\n\nThese criteria pertain to the Screening Visit and Visit 1. If any of these conditions develop after this time, the participant remains in the study. In particular, participants who develop cognitive, motor or psychiatric conditions are retained in the study, although they are excluded from specific testing in which their underlying health condition is an exclusion criteria. Participants that refuse genetic testing and storage at Visit 1 will not be eligible to participate in the study.\n\n* Age greater than or equal to 20 years of age\n* Weigh less than or equal to 300lbs and\u002For body mass index (BMI) is less than or equal to 40\n* Do not have established genetic diseases\n* Are able to perform daily self- care without assistance\n* Are able to walk independently for at least 400 meters without assistance and without developing symptoms\n* Are able to perform normal activities of daily living without shortness of breath (walking or climbing stairs)\n* Do not have cognitive impairment based on screening tests and in the absence of any drug treatment\n* Do not have a history of cardiovascular disease (including angina, myocardial infarction, congestive heart failure, cerebrovascular diseases, uncontrolled hypertension)\n* Do not have a history of diabetes (requiring any medical treatment other than diet and exercise)\n* Do not have active (any activity in the last 10 years) cancer, except for locally limited basal or squamous cell cancer\n* Do not have clinically significant hormonal dysfunction (Laboratory values out of range despite supplementation and\u002For drug treatment)\n* Do not have a history of neurological diseases or birth defects (other than minor anatomical abnormalities, which do not affect physical and\u002For cognitive function)\n* Do not have a history of kidney or liver disease (associated with reduced kidney or liver function)\n* Do not have a history of severe gastrointestinal (G.I.) diseases\n* Do not have muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and\u002For chronic pain)\n* Do not have a history of severe psychiatric conditions (associated with behavioral problems or requiring chronic medical treatment)\n* Do not have any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, H2 blockers and\u002For proton pump inhibitors, or pain medications\n* Do not have important sensory deficits (legally blind and\u002For any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent)\n* Able to read and speak English\n* Do not have joint replacements due to arthritic changes (joint replacements due to previous trauma are ok) or do not have 2 or more joint replacements for any reason\n* Do not meet any exclusionary criteria for 3T MRI and agrees to perform the test\n* Agree to genetic (DNA\u002FRNA) sample collection, analysis, and storage at Visit 1\n\nEXCLUSION CRITERIA:\n\nThese criteria pertain to the Screening Visit and Visit 1. If conditions considered as exclusion criteria for study entry develop any time after the this, the participant remains in the study.\n\nExclusion Criteria Based on Laboratory Assessment:\n\n* HIV virus infection\n* Hepatitis B or C\n* Syphilis\n* WBC \\> 12,000\u002FmcrL\n* Platelets \\\u003C 100,000 or \\>600,000 \u002FmcrL\n* Hemoglobin \\\u003C 11 g\u002FdL\n* Creatinine \\>1.5 mg\u002Fdl or calculated creatinine clearance \\\u003C 50 cc\u002Fmin\n* Bilirubin \\> 1.5 mg\u002Fdl (unless higher levels can be ascribed to Gilbert s disease)\n* ALT, AST or alkaline phosphatase twice the normal serum concentration\n* Corrected calcium \\\u003C 8.5 or \\> 10.7 mg\u002Fdl\n* Albumin \\\u003C 3.1 g\u002Fdl",{"count":118,"type":20},"Background:\n\n\\- The Baltimore Longitudinal Study of Aging (BLSA) is a clinical research program on human aging that began in 1958. Volunteers of different ages join the study when they are healthy, and have follow-up visits for life. Visits last for multiple days. Participants are evaluated for many physical elements as well as for brain function. Physical tests are given. Information on mood, personality, and social aspects of life is also collected. This program has contributed more than any other research project to our understanding of aging.\n\nObjectives:\n\n\\- To characterize the many aspects of the aging process and learn how people can successfully adapt to aging.\n\nEligibility:\n\n\\- Healthy individuals at least 20 years old.\n\nDesign:\n\n* Participants will receive a booklet and video describing the tests they will take.\n* During a 3-day visit at the study hospital, participants will take the following tests:\n* Urine will be collected for 24 hours. Blood samples will be taken. A small piece of muscle tissue may be collected by a needle.\n* A medical questionnaire and a physical exam will be given.\n* Participants hearts will be tested, including with blood pressure tests and electronic monitors. They will breathe into a tube to test their lungs.\n* Participants will perform several exercises, including treadmill walking.\n* Vision, hearing, and taste will be tested.\n* Bone and joint X-rays may be taken.\n* Imaging tests will be given, such as an MRI.\n* Participants will answer questions to test their mental abilities.\n* Participants will return for follow-up visits every few years for life. The tests listed above will be given at every visit.",[59],[213,214,105],"Frailty","Disease Processes","2026-06-11",{"date":217,"type":37},"2026-06-12",{"date":219,"type":37},"2014-02-03",{"name":43,"class":44},{"id":222,"slug":4,"hasResults":10,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":52,"sex":15,"minAge":96,"maxAge":97,"enrollmentInfo":226,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":45},"100358636","NCT03949647","Collection of Bone Marrow Aspirate From Normal Volunteers","* INCLUSION CRITERIA:\n\n  1. Normal healthy males and females, age 18 years and older.\n  2. Agree to DNA\u002FRNA extraction of collected samples, and analysis and storage.\n  3. Health History Questionnaire, based on the American Association of Blood Banks (AABB) guidelines (Attachment 3), is not remarkable for active infection or HIV risk.\n  4. Able to speak and read English.\n  5. Willingness and ability to come to the NIA Clinical Research Unit at MedStar Harbor Hospital in Baltimore every 2 years for a bone marrow aspiration procedure.\n\nEXCLUSION CRITERIA:\n\n1. Unable to verify identification of volunteer by state issued ID card, driver s license, or military ID. Participants earning greater than $600.00\u002Fyear are issued a 1099 form, therefore, positive identification is required.\n2. Unable to provide informed consent\n3. Allergy to Lidocaine (numbing agent) used during bone marrow aspiration procedure\n4. Test results are positive for viral infections such as RPR, HIV, Hepatitis B surface antigen or hepatitis C antibodies. For participants who have been treated for Hepatitis C, screening blood work must show HCV RNA quantitative is not detectable. Researchers are seeking healthy, pristine cells. Due to the ongoing nature of these chronic viral and bacterial infections, the blood cell populations will change. Researchers want to study changing cell populations as a factor of aging only and not those altered by infections.\n5. Ongoing risk factors for HIV or Hepatitis B or C such as: intravenous drug use, non-monogamous unprotected intercourse. These viruses weaken the immune system and cause changes in the white blood cells and their progenitors.\n6. Major medical illnesses such as any type of liquid or solid tumor cancer, history of deep vein thrombosis, auto-immune disorders, organ or bone marrow transplant, or liver, kidney, heart or lung disease.\n7. A medical finding that shows a participant could not safely go through this procedure. (such as Parkinson s disease, dementia or any uncontrolled behavior that would place the participant s safety at risk)\n8. Bleeding conditions such as hemophilia or von Willebrand s disease.\n9. Significant abnormalities are found in the results of blood tests such as elevated liver enzymes (2x normal for MedStar Harbor Hospital Clinical Laboratory parameters), abnormal kidney function, positive viral titers, GFR \\\u003C30.\n10. On any medication that can alter blood cell function such as chronic steroid use, antivirals or past or present chemotherapy (complete list located in the Cytapheresis Screening manual stored in the NIA Cytapheresis Unit).\n11. Radiation therapy past or present.\n12. Inability of researchers to access iliac crest from conditions such as wounds, rashes, or large deposits of adipose tissue that makes localization of the iliac crest difficult.\n13. Organ transplant or any graft such as tissue, bone or skin as we don t know how this impacts progenitor cells.\n\nIn addition, eligible participants may not be able to participate in a specific bone marrow aspiration procedure but might be eligible at a later date. These include:\n\n1. Pregnancy and Nursing Mothers: Females who are pregnant or who have had a pregnancy in the last 6 weeks are temporarily deferred. They may resume participation in the study 6 weeks after delivery or cessation of lactation and have been cleared by their obstetrician or primary care physician.\n2. Medication: Volunteers taking the following medications would be deferred for 2 weeks after course has been completed and volunteer is feeling well: Antibiotics, antifungals, antimalarials.\n3. Temporary steroids (tapers): Deferred for 72 hours after symptoms are resolved and prescription is completed if taken orally, intravenously, or intramuscular. No deferral if taken intranasal or for joint injection.\n4. Hepatitis B immune globulin: Volunteers are deferred 6 months if given after exposure to hepatitis B to ensure the volunteer has not been infected. If administered for prophylaxis, no deferral is necessary.\n5. Live Attenuated Virus Vaccinations: Defer for 4 weeks if symptom-free.\n6. Inactivated (Killed Virus) Vaccinations: Defer for 2 weeks if symptom-free.\n7. Rabies Vaccine: Deferred for 1 year if given for rabies exposure; otherwise accept immediately if symptom-free.\n8. Smallpox Vaccine: Deferred until the scab has separated from the skin spontaneously or 21 days from date of immunization, whichever is longer, if volunteer had no other symptoms or complications. Visual verification of absence of vaccine scab is required. If scab was otherwise removed (not spontaneously separated), defer for 2 months after vaccination date.\n9. Experimental Medication or Unlicensed (Experimental) Vaccine is usually associated with a research protocol and the effect on bone marrow is unknown. Deferral is one year unless otherwise indicated by the Principal Investigator.\n10. Infection or Fever: Deferred until 2 weeks after antibiotics are completed and volunteer is feeling well.\n11. Surgical Procedures: Deferred for 3 months after procedure and released to return to normal activities by primary care physician or surgeon.\n12. Close contact with someone else s blood, accidental needle-stick, treatment for syphilis or gonorrhea Volunteers are deferred for 6 months to insure they have not been infected. Viral\u002Fserology testing will be repeated and verified as negative prior to bone marrow aspiration procedure.\n\n    1. Received money, drugs or other payment for sex or having sexual contact with a prostitute or anyone else who takes money or drugs or other payment for sex\n    2. Has used needles to take drugs, steroids or anything NOT prescribed by their doctor or had sexual contact with anyone who has ever used needles to take drugs or steroids, or anything NOT prescribed by their doctor.\n    3. Had sexual contact with or living with anyone who has hepatitis.\n    4. Had a tattoo using non-sterile needles or reused ink.\n    5. Had a body piercing that used non-sterile needles or multi-use equipment.\n13. Had close contact with someone who had a smallpox vaccination such as touching the vaccination site, handling bedding or clothing that has been in contact with an unbandaged vaccination site to insure they have not been infected: Deferral is 2 months if volunteer is symptom-free.\n14. Anemia\u002FLeukopenia\u002FThrombocytopenia:\n\n    1. Volunteers with a hemoglobin of \\\u003C12.0 for men, \\\u003C11.0 for women or hematocrit \\\u003C38 for men, \\\u003C36 for women may return in 8 weeks to repeat labs to verify anemia. Eligible for procedure once values have returned to normal.\n    2. White blood cell count \\\u003C3.0.\n    3. Platelet count \\\u003C150,000.\n    4. Whole blood donation (450 mL) or bone marrow aspiration procedure: Deferred 56 days from date of last donation as mandated by AABB guidelines.\n    5. Double unit red cell donation: Deferred for 112 days (16 weeks) as mandated by AABB guidelines.\n    6. Platelet or plasma donation: Deferred for 28 days from date of last donation as mandated by AABB guidelines.\n    7. There will be no deferral for apheresis donation as we believe it is safe to perform apheresis and bone marrow aspiration on the same day on normal healthy volunteers. For research purposes, we will perform bone marrow aspiration first if both procedures are done on the same day.\n15. Received blood transfusion: Deferral is for 12 months to ensure volunteer has not acquired an infectious disease. Annual laboratory testing will be repeated prior to bone marrow aspiration procedure.\n16. It is less than six weeks since participation in another research study which is felt by the Principal Investigator to be incompatible with this study. (for example: studies that collect blood, investigational drug studies, vaccine trials, etc.)\n17. Travel:\n\nMalaria-endemic countries: Volunteers who are residents of such countries will be deferred for 3 years after departure from the country if they remain free from unexplained symptoms suggestive for malaria. Residence is defined as a continuous stay of longer than 5 years in a country or countries having any malaria-endemic area. Volunteers who are not prior residents of malaria-endemic countries and travel to a malaria-endemic area will be deferred for 12 months after departure from that area. The duration of travel to a malaria-endemic area is defined as more than 24 hours to less than 5 years. Note that a passage greater than 24 hours through a malaria-endemic area while on route to a malaria-free area is considered a sufficient possible exposure to trigger deferral. (A complete list of malarial-endemic countries is kept in the Cytapheresis Screening Manual and is stored in the NIA Apheresis Unit.)",{"count":227,"type":20},2000,"Background:\n\nBone marrow is the soft material found inside most large bones of the body. Bone marrow produces red blood cells, white blood cells, and platelets that are released into the blood stream. Inside the marrow, these cells start off as young, immature cells called progenitor cells. Researchers want to study these cells in healthy people.\n\nObjective:\n\nTo understand how progenitor cells change with age.\n\nEligibility:\n\nHealthy people ages 18 and older\n\nDesign:\n\nParticipants will be screened with a questionnaire, a physical exam, and blood tests.\n\nParticipants will have a bone marrow aspirate. They will be asked to lie on their stomach or side. A local anesthetic will be injected with a small needle under the skin at the site. A needle will then be placed through the skin and into the hip bone. A small amount of the liquid part of the bone marrow will be taken up into the needle. After the needle is removed, a pressure bandage will be placed on the site.\n\nParticipants will be asked to become a repeat volunteer and have a bone marrow aspirate sample collected once every other year. They will have a physical exam and blood tests before each collection.\n\nThe cells from the collection will be used for genetic testing and research.\n\nParticipants will be in the study for as long as they remain healthy and willing to participate.",[230],"Normal Aging",[232,59,233,234,235,105],"LGR","CD44","Stem Cells","Progenitor Cells","2026-06-02",{"date":238,"type":37},"2026-06-03",{"date":240,"type":37},"2019-05-08",{"date":242,"type":20},"2050-12-31",{"name":43,"class":44},{"id":245,"slug":4,"hasResults":10,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":52,"sex":15,"minAge":96,"maxAge":188,"enrollmentInfo":250,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":4,"leadSponsor":262,"locationsCount":45},"100157632","NCT01324206","Development of 3T Magnetic Resonance Research Methods for NIA Studies","Development of Magnetic Resonance Imaging and Spectroscopy Research Methods for NIA Studies","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n* Ability of subject to understand the study and stated willingness to comply with all study procedures.\n* Male or female, age \\> 18years.\n* Able to speak and read English.\n* Capable of providing informed consent.\n* Subjects or persons identified by an investigator to have a condition of interest for exploratory studies as it relates to aging. These participants are not being scanned for diagnostic purposes.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Has condition and\u002For non-removable device contraindicated for MRI as per the MRI eligibility form.\n* Weight \\> 300lbs (MRI scanner weight limit)\n* Is currently pregnant or a nursing mother.",{"count":251,"type":20},1000,"Background:\n\n\\- Magnetic resonance imaging (MRI) studies provide important information on the structure and function of various body systems, including the brain, muscles, joints, heart, and blood vessels. Scientific applications of MRI scans often use techniques that need to be modified or refined before they are used in clinical studies. To develop and modify these techniques for the new Philips 3T Achieva whole-body MRI scanner, researchers are interested in conducting trial MRI scans on healthy individuals and individuals with conditions that require imaging studies.\n\nObjectives:\n\n\\- To conduct preliminary trials of the 3T MRI facility to develop and refine MRI scanning procedures.\n\nEligibility:\n\n\\- Individuals at least 18 years of age who are able to have magnetic resonance imaging.\n\nDesign:\n\n* Participants will be screened with a full medical history and physical examination, as well as blood and urine tests.\n* Participants will have an MRI scan using the 3T scanner. Some scans may require the use of a contrast agent or radiotracer, which is a small amount of radioactive substance that will be injected before the start of the scan. Some participants may be asked to perform tasks of thinking and movement while in the scanner, in order to test the procedures required for a functional MRI scan.\n* No treatment will be provided as part of this protocol.",[254],"Normal Physiology",[256,121,105],"Magnetic Resonance Imaging","2026-05-29",{"date":259,"type":37},"2026-06-01",{"date":261,"type":37},"2008-11-03",{"name":43,"class":44},{"id":264,"slug":4,"hasResults":10,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":52,"sex":15,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":45},"100586234","NCT06912724","Pediatric Neuroimaging","A Cross-Sectional Observational Feasibility Pilot Study in Pediatric Neuroimaging: Quantifying White Matter Microstructural Changes in Adolescents With Multidimensional Assessment of Pubertal Stage","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, 9 to 14 years of age.\n* In good general health\n* Ability of parent\u002Fguardian to understand and the willingness to sign a written informed consent document.\n* Ability of participant to participate in the assent process and willingness to sign a written informed assent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Any known brain abnormalities (e.g. tumor, periventricular leukomalacia, microcephaly) or history of medical conditions known to affect cerebral micro or macro-structural integrity (e.g., epilepsy, history of stroke, head injury with a loss of consciousness of one hour or more).\n* History neurodevelopmental delay or disorder, learning disability, intellectual disability (formerly referred to as mental retardation), autism spectrum disorders, and attention deficit\u002Fhyperactivity disorder (ADHD)), as evaluated history, physical and by the SDQ, and if indicated, the KSADS\n* History of psychiatric disorder as evaluated by history and the SDQ, and if indicated, the KSADS.\n* History of prematurity (\\\u003C 32 weeks gestational age).\n* History of endocrine abnormalities, including diagnosed disorders of thyroid, growth, and precocious or delayed puberty\n* History of major medical conditions or chronic medical conditions. Examples include neurological disorders, medical or genetic conditions with associated neurological manifestations, malnutrition, conditions raising risk of micronutrient or macronutrient deficiencies (e.g. inflammatory bowel disease), untreated chronic anemia, cardiovascular disease, significant lung disease (e.g. bronchiectasis), significant liver disease, significant kidney disease, significant autoimmune condition, and chronic infections (e.g. HIV, hepatitis B).\n* Pregnancy.\n* Not eligible to have an MRI as per the MRI eligibility form and the safety standards of the NIA 3T MRI center.\n* Presence of hardware (e.g. orthodontic braces) that may interfere with MRI data quality.\n* Any other condition which in the investigator s opinion may adversely affect the subject s ability to complete the study or its measures or which may pose significant risk to the subject.","9 Years","14 Years",{"count":272,"type":20},80,"Background:\n\nPuberty is a normal part of life. Many big changes occur in all parts of the body as a child matures into an adult. Researchers in this study want to find out more about how the brain changes during puberty.\n\nObjective:\n\nTo study changes that occur in the brain before, during, and after puberty.\n\nEligibility:\n\nHealthy children aged 9 to 14 years.\n\nDesign:\n\nParticipants will have 2 clinic visits. Each visit will last up to 4 hours.\n\nIn the first visit, participants will be screened:\n\nThey will have a physical exam with blood tests.\n\nThey will complete a mental health questionnaire on a computer.\n\nThey will undergo a mock magnetic resonance imaging (MRI) scan. Participants will be made comfortable as they lie on the table and slide into the big tube. They will learn what it feels and sounds like to lie still inside a real MRI.\n\nAt the second visit, participants will have more tests:\n\nThey will have a physical exam with blood tests. This time the doctor will check for their stage of puberty. The doctor will look at and touch their genitals and breasts.\n\nThey will have a real MRI exam.\n\nAn x-ray will be taken of their hand and wrist. This will show how their bones are maturing.\n\nThey will have a DEXA scan. They will lie on a table while a machine uses x-rays to measure the makeup of their bodies, including bone, muscle, and fat.\n\nThey will have a 3D body scan. They will wear tight clothes and a shower cap. They will stand on a platform while sensors take pictures of their body.",[275],"Neurogimaging",[277],"Pediatric Neuroimaging Pubertal Adolescents","2026-05-14",{"date":280,"type":37},"2026-05-15",{"date":282,"type":37},"2025-04-21",{"date":284,"type":20},"2027-05-01",{"name":43,"class":44},{"id":287,"slug":4,"hasResults":10,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":52,"sex":15,"minAge":140,"maxAge":97,"enrollmentInfo":291,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":45},"100536809","NCT06269653","Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, age \\>= 20years.\n* BMI \\>20 and \\\u003C30.\n* In good general health as evidenced by medical history\u002Fexam\u002Flaboratory.\n* IL6\\\u003C 3.5 pg\u002FmL.\n* Ankle Brachial Index (ABI) \\> 0.9.\n* No history of increased bleeding due to either a known medical condition or an undiagnosed cause.\n* Does not currently smoke\u002Ftobacco use.\n* Eligible for muscle biopsy procedures.\n* Is not allergic to lidocaine or other local anesthetics.\n* Able to speak and read English.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Routinely taking (more than 2x\u002Fweek) non-steroidal anti-inflammatory agents (NSAIDs) and unwilling to stop taking them for the duration of the study.\n* Taking medications that could increase the chance of bleeding such as anticoagulants\u002Fantiplatelet such as Coumadin, Plavix, and Heparin. Low dose (81mg) aspirin use is okay.\n* Is unable to reach down to perform wound care of the lower legs.\n* Has laboratory evidence of diabetes at screening (fasting glucose \\>= 126) and\u002For diabetes requiring treatment, or treatment with any glucose lowering drug(s).\n* Has current or history of inflammatory and\u002For autoimmune diseases.\n* History of keloid formation.\n* Researchers are unable to access biopsy sites due to conditions such as wounds, rashes, or large deposits of adipose tissue.\n* Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment.\n* Has any chronic disease that the study PI considers as a significant comorbidity that affects health and life expectancy.\n* Has established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder).\n* Has autoimmune diseases such as Hashimoto s thyroiditis, Myasthenia Gravis, or Rheumatoid arthritis.\n* Has severe mobility disability as evidenced by inability to walk without aids, perform activities of daily living and to reach down to lower legs to perform wound care.\n* Has had active cancer on treatment in the last 10 years.\n* Has muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and\u002For chronic pain).\n* Has any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, or pain medications.\n* Has important sensory deficits such as legally blind.\n* Is currently pregnant or a nursing mother.\n* Has history of, or laboratory evidence of HIV, Hepatitis B or C at Screening.\n* Has laboratory evidence of Platelets \\\u003C 100,000 or \\>600,000 k\u002Fmicroliter.\n* Has a positive urine drug screen unless taking prescribed medication and at the discretion of the PI.\n* Has a current illness that as judged by the study physician substantially increases the risks associated with performing a biopsy procedure.\n* Has a history of an active bleeding disorder such as haemophilia or Von Willebrand disease.\n* Is claustrophobic and\u002For is not eligible to perform MRI as per the MRI eligibility form.\n* Has a hip or knee replacement or other medical conditions that prevents MRI research scans from being performed.\n* Has a diagnosis of cognitive impairment that clearly prevents the participant from providing informed consent.\n* Has a history of, or evidence of heart disease including unstable angina, myocardial infarction, congestive heart failure, cerebrovascular diseases, uncontrolled hypertension, uncontrolled cardiac arrythmias, moderate to severe valvular disease.\n* Has a history or has chronic liver disease as evidenced by medical history or ALT, AST, or alkaline phosphatase twice the normal serum concentration.\n* Drinks more than three drinks of alcohol per day on average.\n* Has a history of, or evidence of chronic kidney disease or serum creatinine \\>1.1 mg\u002FdL.\n\nParticipants must be able to speak and read English. The reason for this is for safety reasons especially as it relates to the muscle biopsy procedures. Participants will be required to provide medication history and to understand and report any problems post muscle biopsy to the research medical staff. In addition, the medical staff will be contacting the participant after the biopsies to ensure that they are recovering and do not have significant side effects for which the participant must be able to clearly verbalize for the medical staff to determine if additional observation or treatment is indicated.",{"count":292,"type":20},75,"Background:\n\nProteins are essential to the health and structure of the cells that make up body tissues. Most proteins become damaged over time and are replaced with new ones. This process is called \"protein turnover.\" Stress, disease, and aging can affect this process. Researchers want to better understand how aging affects protein turnover.\n\nObjective:\n\nTo measure rates of protein turnover in healthy adults.\n\nEligibility:\n\nHealthy people aged 20 years and older with a body mass index between 20 and 30.\n\nDesign:\n\nParticipants will have 6 study visits over 4 to 6 weeks. They will fast 12 hours before each visit.\n\nParticipants will be screened. They will have a physical exam, with blood and urine tests and tests of their heart function. They will lie down while blood pressure cuffs are used on their arms and legs.\n\nParticipants will be given bottles of heavy water to drink at home on a schedule for 21 days. Each bottle holds about 3.5 tablespoons. Heavy water is odorless, colorless, and tasteless, like normal drinking water. It is safe to drink and has been used in research for many years.\n\nParticipants will have tests during study visits, including:\n\nImaging scans of a leg.\n\nExercise on a treadmill.\n\nBiopsies of muscle, skin, and fat: Small samples of tissue will be cut from the calf and abdomen.\n\nResting metabolic rate: Participants will lie still and breathe into a mask for 20 minutes.\n\nKnee\u002Fgrip strength: Participants will do strength tests with their legs. They will squeeze a device with their hands.\n\nD3-Creatine: Participants will take 1 pill of D3-Creatine, which occurs naturally in muscle.",[121],[296,297,298,299,300],"PROTEIN TURNOVER","Metabolic","Mononucleated Cells","Mitochondrial","Peripheral","2026-03-19",{"date":303,"type":37},"2026-03-20",{"date":305,"type":37},"2024-06-26",{"date":307,"type":20},"2027-03-01",{"name":43,"class":44},""]